Clearbridge Investments LLC Cuts Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Clearbridge Investments LLC reduced its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 11.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,185,967 shares of the company’s stock after selling 148,916 shares during the period. Clearbridge Investments LLC owned 2.61% of Omnicell worth $44,628,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of OMCL. Avory & Company LLC boosted its holdings in shares of Omnicell by 22.7% during the 3rd quarter. Avory & Company LLC now owns 153,776 shares of the company’s stock worth $6,926,000 after purchasing an additional 28,416 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Omnicell by 15.1% during the 3rd quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company’s stock worth $231,374,000 after purchasing an additional 674,824 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in shares of Omnicell by 321,488.8% during the 4th quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company’s stock worth $39,814,000 after purchasing an additional 1,057,698 shares during the last quarter. Public Sector Pension Investment Board acquired a new position in Omnicell in the third quarter valued at approximately $2,517,000. Finally, Ontario Teachers Pension Plan Board acquired a new position in Omnicell in the third quarter valued at approximately $984,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Stock Up 1.0 %

Shares of Omnicell stock opened at $32.24 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.13 and a current ratio of 2.38. Omnicell, Inc. has a 1 year low of $25.69 and a 1 year high of $77.14. The business has a 50 day moving average price of $28.59 and a 200 day moving average price of $31.23.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Benchmark reissued a “buy” rating and issued a $38.00 target price on shares of Omnicell in a research report on Tuesday, April 30th. Wells Fargo & Company cut their target price on Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $42.20.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.